Last reviewed · How we verify
Remsima IV
At a glance
| Generic name | Remsima IV |
|---|---|
| Sponsor | Celltrion |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (PHASE1, PHASE2)
- MIS-C Comparative Effectiveness Study (PHASE2, PHASE3)
- TITRATE (inducTIon for acuTe ulceRATivE Colitis) (PHASE4)
- A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
- Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD (NA)
- A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remsima IV CI brief — competitive landscape report
- Remsima IV updates RSS · CI watch RSS
- Celltrion portfolio CI